Interview with Jeffrey Davis, CEO of Access Pharmaceuticals
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
Profiles
BioDelivery Sciences (NASDAQ: BDSI): Restarting the Catalyst Cycle
BDSI focuses on the niche market of pain management and supportive cancer care.
DATATRAK: Low Valuation, Improving Results
DATATRAK International Inc. (OTC: DATA.PK) is a clinical trials information technology (IT) and services company that is focused on increasing its share of an estimated $720 million (M) Electronic Data Capture (EDC) market opportunity.
Positive Phase II Data for Peregrine’s Lung Cancer Treatment
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.
Inovio Biomedical (AMEX: INO): A DNA Vaccine Delivery Innovator
Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
CardiAQ Valve Technologies Announces New Data, New Board Members
CVT’s system, currently under development, is the first self-conforming and self-anchoring technology for transcatheter mitral valve implantation (TVMI).
Cytori’s Cardiac Celution: Encouraging Interim Data
In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction and chronic myocardial ischemia.
[Company Profile] Urovalve
Men with acute or chronic urinary retention find that the condition limits their normal activities, causes embarrassment, and poses serious health risks. Urovalve of Newark, NJ, seeks to replace catheterization with an updated treatment that returns bladder control to the patient.
OneMedPlace Interviews Richard T. Schumacher, CEO of Pressure Biosciences
Pressure Biosciences CEO Rick Schumacher discusses the company’s proprietary technology and the high-profile clients that are using it.
[Company Profile] DATATRAK International
Before a new medical device or drug hits the market, before the flashy ad campaigns, even before government approval, there are clinical trials.